These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

674 related items for PubMed ID: 18446088

  • 1. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
    Golubchik P, Sever J, Zalsman G, Weizman A.
    Int Clin Psychopharmacol; 2008 Jul; 23(4):228-31. PubMed ID: 18446088
    [Abstract] [Full Text] [Related]

  • 2. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B.
    Clin Neuropharmacol; 2009 Dec; 32(4):179-82. PubMed ID: 19644227
    [Abstract] [Full Text] [Related]

  • 4. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
    Levin FR, Evans SM, Brooks DJ, Garawi F.
    Drug Alcohol Depend; 2007 Feb 23; 87(1):20-9. PubMed ID: 16930863
    [Abstract] [Full Text] [Related]

  • 5. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.
    Sleep Med; 2007 Jan 23; 8(1):18-30. PubMed ID: 17157069
    [Abstract] [Full Text] [Related]

  • 6. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 23; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 23; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group.
    Biol Psychiatry; 2007 Jun 15; 61(12):1380-7. PubMed ID: 17137560
    [Abstract] [Full Text] [Related]

  • 9. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P.
    Child Care Health Dev; 2006 Sep 15; 32(5):575-83. PubMed ID: 16919137
    [Abstract] [Full Text] [Related]

  • 10. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 15; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 11. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

  • 12. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 May 01; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 13. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
    Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE.
    Ann Clin Psychiatry; 2010 May 01; 22(2):94-102. PubMed ID: 20445836
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.
    Aust N Z J Psychiatry; 2007 Mar 01; 41(3):222-30. PubMed ID: 17464703
    [Abstract] [Full Text] [Related]

  • 15. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder.
    Bukstein OG, Kolko DJ.
    J Clin Child Psychol; 1998 Oct 01; 27(3):340-51. PubMed ID: 9789193
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 01; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 17. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA.
    Arch Gen Psychiatry; 2007 Feb 01; 64(2):218-24. PubMed ID: 17283289
    [Abstract] [Full Text] [Related]

  • 18. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW, Earl CQ, Arora S.
    Curr Med Res Opin; 2006 Dec 01; 22(12):2457-65. PubMed ID: 17257460
    [Abstract] [Full Text] [Related]

  • 19. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S.
    Biol Psychiatry; 2005 Mar 01; 57(5):456-63. PubMed ID: 15737659
    [Abstract] [Full Text] [Related]

  • 20. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder.
    Cheon KA, Cho DY, Koo MS, Song DH, Namkoong K.
    Biol Psychiatry; 2009 Apr 01; 65(7):564-70. PubMed ID: 19150055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.